Alexion Pharmaceuticals, Inc.ALXN announced that the phase III study, PREVENT, on lead drug Soliris was successful. The Prevention of Relapses and Evaluation of Eculizumab in NMOSD Treatment (PREVENT) ...
Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris ® (eculizumab) in patients with anti-aquaporin-4 (AQP4) auto antibody-positive ...
Amgen Inc. AMGN announced positive top-line data from the phase III study evaluating its biosimilar candidate, ABP 959, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback